Cardiovascular

The journey to better women's heart health starts with having more data, said Nanette Kass Wenger, MD, MACC, MACP, FAHA, professor of cardiology at Emory University School of Medicine, during the Simon Dack Keynote Lecture, which opened the 67th Scientific Session of the American College of Cardiology.

The study will be presented during the 67th American College of Cardiology Scientific Session in Orlando, Florida.

A study being presented at the upcoming meeting of the American College of Cardiology found a dose–response relationship between walking and reduced heart failure risk.

Adults with obesity have an earlier onset of incident CVD, a greater proportion of life lived with CVD morbidity, and shorter overall survival compared with adults with normal BMI; and the proportion of adults with incident CVD events was significantly higher in adults who were classified as overweight or obese compared with adults with normal BMI, according to a study in JAMA Cardiology.

In the next phase of the program, researchers will dig into the data they have gathered so far to identify the best practices for reducing 30- and 90-day readmission rates.

According to the Medicare Payment Advisory Commission (MedPAC), hospital readmission rates have fallen following implementation of the Hospital Readmissions Reduction Program (HRRP), and HRRP did not have a negative impact on mortality rates.

With 4 in 10 cardiomyopathies having genetic links, there is a need for relatives of patients with cardiomyopathy to be screened in order to prevent early death, according to a recent study published in European Heart Journal.

A new study published in the February issue of the New England Journal of Medicine found that patients that received radiofrequency catheter ablation compared with traditional drug therapies for atrial fibrillation (AF) had significantly lower hospitalization and mortality rates.

Higher resting heart rate (HR) and increases in HR over time are associated with increased risk of adverse cardiovascular (CV) and non-CV events, such as incident heart failure and all-cause mortality, according to a study published in JAMA Cardiology.

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

Empagliflozin (Jardiance) and another SGLT2 inhibitor, canagliflozin (Invokana) have been competing aggressively; both have clinical trial results showing cardiovascular benefits.

The annual meeting of the American College of Cardiology (ACC), which runs March 10-12, 2018, in Orlando, Florida, will open with cardiovascular outcomes results for the PCSK9 inhibitor alirocumab (Praluent). The meeting also features updates on anti-inflammatory drugs, the use of SGLT2 inhibitors in heart failure, and how cardiology is shifting to new healthcare delivery models.

Researchers were especially concerned about barriers for patients with familial hypercholesterolemia, whose needs would seem clear cut but who nonetheless faced costly hurdles, such as genetic testing.

A randomized trial of eConsults for cardiology referrals from primary care resulted in significant reductions in total cost of care compared with traditional face-to-face consultations.

Reimbursement structures and population demographics change the way hospitals approach heart failure, explained Amar Bhakta, MD, of Rush University Medical Center.

The same mechanisms that cause those with long-term HIV infection to suffer higher rates of heart attacks or strokes put children born with disease at early risk of cardiovascular disease, according to a new study.

The announcement comes after CMS canceled an Obama-era proposal for mandatory bundled payments in cardiac care, as well as a mandatory expansion of a program in joint replacements.

The announcement comes after CMS canceled an Obama-era proposal for mandatory bundled payments in cardiac care, as well as a mandatory expansion of a program in joint replacements.

A newer method for calculating low-density lipoprotein (LDL) cholesterol is more accurate than the older method that required people fast before blood was drawn.

Although patients and physicians both recognize the need to discuss obesity, the lack of resources, time, and expertise often prevents physicians for offering care and patients from asking for it, explained Todd Hobbs, MD, Novo Nordisk’s vice president and chief medical officer.

In 2017, The American Journal of Managed Care® (AJMC®) covered conferences on a range of topics: oncology, diabetes, managed care, and much more. however, the most-read coverage from conferences that AJMC® attended mostly focused on cardiology trial results, particularly the cardiovascular results of diabetes medications.

Trial results have shown that alirocumab (Praluent) is safe and effective across patient populations, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.

An interview with one of the authors of a large observational study that has seen findings consistent with recent cardiovascular outcomes trials in SGLT2 inhibitors.

Currently, clinical guidelines offer little guidance on deintensifying care, which is critical for balancing overuse and underuse of services.